In this whitepaper we describe the application of claraT to an RNA-Sequencing dataset of malignant melanoma cancer patients treated with Ipilimumab.
This evaluation highlights that a subgroup of tumors within the cohort have strong immune activation leading to improved overall survival compared to other subgroups with activation of EMT and MEK pathway related signatures. Importantly these subgroups represent a consensus between multiple gene expression signatures allowing the discovery of robust biologies.
Overall this article demonstrates the utility of the claraT software solution in maximising the understanding of gene expression data by applying multiple signatures simultaneously. claraT provides a cost effective solution for biomarker discovery and translational research whilst saving resource and analysis time.